Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
paywall - Nature
Tumours respond more readily to radiation and other therapies in mice without a specific protein in their dendritic cells.
Tinkering with immune cells gives cancer treatment a boost
Tumour growth is constrained in bioengineered mice with dendritic cells
Research in mice suggests that blocking a key protein in certain immune cells could boost the effectiveness of
https://www.nature.com/articles/d41586-023-03747-3
Genomic Landscape and Actionable Mutations of Brain Metastases derived from Non-Small Cell Lung Cancer: a systematic review
24 November 2023
I want to see the London Eye before I die - my mum's helping me with bucket list
1 DEC 2023
thanks -
I caught up with part of it here
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173306429
nice discovery on your part - Thank You
ccie1024
David A Reardon, E Antonio Chiocca
Neoantigen vaccine spurs immune response in glioblastoma
Posted date
December 19, 2018
[NeoVax]
“This is the first time it has been shown that a vaccine can generate immune cells against the tumor that can traffic from the bloodstream into a glioblastoma tumor,” said David Reardon, MD, senior author of the study. Reardon is clinical director of the Center for Neuro-Oncology at Dana-Farber.
“This personalized approach to creating a vaccine that can reinvigorate a patient’s immune system represents the culmination of a collaboration between experts in neurosurgery and neuro-oncology,” said co-author Antonio Chiocca, MD, chair of the Department of Neurosurgery at Brigham and Women’s. “We’re thrilled to have played a role in this innovative work.”
https://www.dana-farber.org/newsroom/news-releases/2018/neoantigen-vaccine-spurs-immune-response-in-glioblastoma
Ethan Chen
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173294396
Alex Ling
Postdoctoral Research Fellow
Boston, Massachusetts, United States
I am a postdoctoral fellow in Dr. Antonio Chiocca's lab at Brigham and Women's Hospital. My work is aimed at understanding how standard of care therapies influence the efficacy of immunogenic viral therapies in glioblastoma. My expertise lies in computational predictions of drug/drug combination efficacy, genomic bioinformatics, and in vitro/in vivo studies of oncolytic viral therapies in glioblastoma.
https://www.linkedin.com/in/alex-ling-b0198874
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca
https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noad211/7444576?login=false
hyperopia
thank you for your response - esp. this part
CHM meeting date .......... Submission deadline
Whose Dr Chiocca?
What was stated incorrectly?
Sawston Business Park becomes world-class facility producing
NW Bio cancer vaccine
Published: 15:44, 25 February 2022 | Updated: 11:46, 03 March 2022
The Maryland-based biotechnology company has been developing personalised immunotherapy products designed to treat solid tumour cancers, with input from its R&D team at Sawston. These therapies, it says, are “designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe”.
This milestone follows approval by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at the Sawston facility for compassionate use cases, plus approval by the Human Tissue Authority (HTA) of a license for collection and processing of human cells and tissues for medical purposes. Under this UK regulatory program, the vaccine is identified as ADCV (‘autologous dendritic cell vaccine’).
As previously reported, the MHRA license was received in December of 2021, following nearly two years of preparations
More
https://www.cambridgeindependent.co.uk/business/sawston-business-park-becomes-world-class-facility-producing-9242093/
6.800.000 short sales
DD - Thanks for posting ......
There are a fair amount of smart people here who think Linda's obfuscation
was intentional ... and we MAA in December .....
Example of MAA acceptance
Nymox Pharmaceutical Corporation
IRVINE, Calif., Oct. 26, 2023
Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the U.K. authorities, at U.K. Medicines & Healthcare products Regulatory Agency (MHRA). The formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted September 25, 2023. The new submission includes England, Wales, Scotland and Northern Ireland. The Company will continue to provide further information, including other expected submissions, when the information becomes available.
Note - acceptance appears to have taken around 30 days
https://finance.yahoo.com/news/nymox-reports-nymozarfex-marketing-application-140000074.html
Example of MHRA acceptance of MAA
Nymox Pharmaceutical Corporation
October 26, 2023·
IRVINE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the U.K. authorities, at U.K. Medicines & Healthcare products Regulatory Agency (MHRA). The formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted September 25, 2023. The new submission includes England, Wales, Scotland and Northern Ireland. The Company will continue to provide further information, including other expected submissions, when the information becomes available.
https://finance.yahoo.com/news/nymox-reports-nymozarfex-marketing-application-140000074.html
Note - in this example acceptance took around 30 days
Overview
From 1 January 2024, the EC Decision Reliance Procedure (ECDRP) will be replaced by the new International Recognition procedure (IRP). The Mutual Recognition/Decentralised Reliance Procedure (MRDCRP) will be incorporated under the umbrella of IRP.
ECDRP and MRDCRP submissions received before 1 January 2024 will be processed under the existing practices. For ECDRP applications, the Committee for Medicinal Products for Human Use (CHMP) positive opinion (but not necessarily the European Commission Decision) should be received before 31 December 2023.
More (Have not read)
https://www.gov.uk/government/publications/international-recognition-procedure/international-recognition-procedure
Guidance
Eligibility Checker and submitting your Marketing Authorisation application
Updated 20 November 2023
Guidance on how to complete the Eligibility Checker and submit an International Recognition Procedure for a Marketing Authorisation Application (MAA).
Overview
From 1 January 2024 applicants will be able to apply for a marketing authorisation under the International Recognition procedure (IRP). This will replace the EC Decision Reliance Procedure (ECDRP). The Mutual Recognition/Decentralised Reliance Procedure (MRDCRP) will be incorporated under the umbrella of IRP.
More (have not read)
https://www.gov.uk/government/publications/international-recognition-procedure/eligibility-checker-and-submitting-your-marketing-authorisation-application
February 1, 2024
Booth 113
https://sno2023.eventscribe.net/exhibitors/floorplan/floorplan.asp
Click booth - scroll 113
Novacure is directly opposite them on the other side of the floor plan
Dendritic Cell Discovery Holds Key for Developing Novel Vaccines
The finding has major implications for the generation of a strong CD8 T lymphocyte response.
Nov 3 2023
https://www.technologynetworks.com/biopharma/news/dendritic-cell-discovery-holds-key-for-developing-novel-vaccines-380666
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
18 November 2023
I imagine - when MHRA accepts NWBO submission .....
the judge in the NWBO vs
market makers
Canaccord Genuity LLC,
Citadel Securities LLC,
G1 Execution Services LLC,
GTS Securities LLC,
Instinet LLC,
Lime Trading Corp.,
Susquehanna International Group LLP,
Virtu Americas LLC
will go bonkers
because he will then know DCVax-L is a real therapeutic (potentially)
capable of saving (000) of lives.
abc - 2nd response
again, thanks for fixing my thinking .... but for my own sanity
somehow I thought Laura H. Posner was involved ....
https://www.cohenmilstein.com/professional/laura-h-posner
because of this link
https://www.cohenmilstein.com/case-study/northwest-biotherapeutics-inc-securities-litigation
see related professionals
anyway, thanks again
success after success after success - NWBO
AUG 29 2023
Northwest Biotherapeutics Announces Completion of Prerequisites,
and Plans for Submission of Marketing Authorization Application
Mar 20 2023
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License
for Commercial Manufacturing at Sawston, U.K. Facility
Nov 17 2022
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial
of DCVax®-L for Glioblastoma
Aug 23 2022
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan
(PIP) by MHRA: PIP Approval Is A Pre-Requisite for Application for
Approval of A New Medicine for Adult Patients
Jul 6 2022
Northwest Biotherapeutics Announces Filing of Application for License for
Commercial Manufacturing at Sawston, UK Facility
Feb 17 2022
Northwest Biotherapeutics Announces Commencement Of Cancer
Vaccine Production At Its Sawston, UK Facility
Dec 21 2021
Northwest Biotherapeutics Announces MHRA Approval Of License for
GMP Manufacturing At Sawston, UK Facility
Oct 28 2021
Northwest Biotherapeutics Announces HTA License Issued and
MHRA Inspection Conducted for Sawston, UK Facility
Mar 16 2021
Northwest Biotherapeutics Announces Development Completed for Initial
Production Capacity of Sawston, UK Facility
Oct 20 2020
Northwest Biotherapeutics Announces Data Lock of Phase III Trial
you can't find ANY big pharm companies
this far along in the GBM clinical process .............
To anyone -
Whats email address for the lady judge in Citadel case .....
Want to send her this -
or you can send it
T cell Response Dynamics in Phase 3
Glioblastoma Patients Immunized
with Autologous Dendritic
Cells pulsed with Autologous
Tumor Lysate
November 17, 2023
Marnix Bosch
Northwest Biotherapeutics, inc
Linda M. Liau
UCLA
Los Angeles, California, United States
Keyoumars Ashkan
Kings College Hospital
London, United Kingdom
SNO 28th Annual Meeting
https://sno2023.eventscribe.net/index.asp
https://sno2023.eventscribe.net/agenda.asp?BCFO=G%7CM%7CP&pfp=days&startdate=11%2F17%2F2023&enddate=11%2F17%2F2023
Thanks ATLnsider for heads-up
By June 2024 GBM patients will be receiving DCVax-L based on earlier MHRA approval.
The patients will come from:
-- the UK
-- Europe
-- Canada
-- United States
GBM is a death sentence so patients will act quickly and come from all over the world.
Big pharm contributed -0- to the technology and trials that made this possible. They are
not necessary.
Six months after delivering DCVax-L to patients - I am hoping NWBO will begin a DCVax-Direct
trial for lung cancer. I am hoping 6 locations and 150 patients in the UK would be sufficient
for the MHRA.
Look up annual lung cancer deaths
My goodbye letter to the people I love as brain cancer slowly shuts off my body
'However wide or narrow, I’m glad our paths in life crossed. Thank you for sharing your time with me.'
ByMatthew Collins
04:00, 12 NOV 2023
Dying man, 35, reveals how his HEADACHES turned out to be terminal brain cancer - and his only hope is a £250,000 tumour-killing injection not yet offered on the NHS
The 35-year-old compared his headaches to a 'bomb going off' inside his head
He blames his 4x4x4cm brain tumour for years of anxiety and depression
By REBECCA WHITTAKER FOR MAILONLINE
PUBLISHED: 10:54 EST, 12 November 2023 | UPDATED: 10:58 EST, 12 November 2023
Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors
Published: November 06, 2023
DOI: 10.7759/cureus.48412
Peer-Reviewed
This is about lung cancer.
This is not about DCVax-Direct
But the story line and results very much follow along the lines of a woman in the Direct trial who had a tumor the size
of a grapefruit(?) and which Direct eliminated. The story was conveyed by Linda Powers at a meeting
Lung cancer vaccine(Northwest Biotherapeutics, Inc.)
Drug Type Therapeutic vaccine
Synonyms DCVax-Lung,
DCVax-LB,
Lung cancer vaccine
Target -
Mechanism Immunostimulants
Therapeutic Areas
Neoplasms,
Nervous System Diseases
Active Indication
Glioblastoma Multiforme,
Glioblastoma
Inactive Indication Lung Cancer
Originator Organization Northwest Biotherapeutics, Inc. Northwest Biotherapeutics, Inc.
https://synapse.patsnap.com/drug/dc4dedbd2c3349afaa421da11af4c2ce
VAL-083 Fails to Outperform SOC in Glioblastoma
October 31, 2023
Chris Ryan
Man, 35, given devastating cancer diagnosis after suffering from 'crippling' symptoms
Matthew Collins was diagnosed with an incurable brain cancer and now faces a "very" poor prognosis.
By DIANA BUNTAJOVA
Tue, Nov 7, 2023
A Doctor With Brain Cancer Is Helping Transform Its Treatment
October 13th
Note - the vaccine is never identified by name